PDCD1 and non-small cell lung carcinoma: MiR-155 can directly target cytokine response elements to suppress the expression of the programmed cell death protein 1 (PD-1) gene and is considered a potential biomarker for evaluating prognosis and therapeutic response in NSCLC (20).